English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/60645
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Title

Increased serum baseline tryptase levels and extensive skin involvement are predictors for the severity of mast cell activation episodes in children with mastocytosis

AuthorsÁlvarez-Twose, Iván; Vaño-Galvan, Sergio; Sánchez-Muñoz, Laura; Morgado, J. M.; Matito, Almudena; Orfao, Alberto ; Escribano, Luis
Issue Date2012
PublisherJohn Wiley & Sons
CitationAllergy 67(6): 813-821 (2012)
Abstract[Background]: Despite the good prognosis of pediatric mastocytosis, some patients suffer from severe mast cell (MC) mediator-associated symptoms. The aim of this study was to identify predictors for severe MC mediator release symptoms in children with mastocytosis in the skin (MIS). [Methods]: Serum baseline total tryptase (sbT) levels in 111 children with MIS - 80 maculopapular cutaneous mastocytosis/plaque mastocytosis, 22 nodular mastocytosis, and nine diffuse cutaneous mastocytosis - were investigated as a predictive biomarker for the occurrence of MC mediator-related signs and symptoms within the first 18 months after disease onset. [Results]: Twelve children (11%) who showed extensive cutaneous disease involving >90% of body surface area (BSA) suffered from severe symptoms requiring hospitalization, with (n = 5) or without (n = 6) management in the intensive care unit (ICU) owing to life-threatening complications. The median sbT was significantly (P < 0.001) higher in patients with extensive cutaneous disease vs those with <90% of BSA involved (45.5 vs 5.2 μg/l, respectively), as well as in children with grade 4 (severe mastocytosis-related symptoms requiring emergency therapy and hospitalization) vs those with grade <4 (46.2 vs 5.2 μg/l, respectively). Receiver operating characteristics curve analyses showed that the optimal cutoff s for sbT to predict the need for daily antimediator therapy, hospitalization, and the management in an ICU were 6.6, 15.5, and 30.8 μg/l, respectively (sensitivity and specificity of 77% and 79%, 100% and 95%, and 100% and 96%, respectively). [Conclusions]: Increased sbT in association with extensive cutaneous involvement identifies patients at risk for severe MC activation events in pediatric mastocytosis.
DescriptionPMCID: PMC3349769.-- et al.
Publisher version (URL)http://dx.doi.org/10.1111/j.1398-9995.2012.02812.x
URIhttp://hdl.handle.net/10261/60645
DOI10.1111/j.1398-9995.2012.02812.x
Identifiersissn: 0105-4538
e-issn: 1398-9995
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
Increased serum.pdf634,61 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.